[1] Stone J, Martin NK, Hickman M, et al. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One, 2016,11:e0156213.
[2] 袁小珍, 陈伟烈, 张健珍. 广东地区丙型肝炎患者HCV基因亚型分析. 国际医药卫生导报, 2012, 18:2649-2651.
[3] Zhou B, Cai GFF, Lv HKK, et al. Factors correlating to the development of hepatitis c virus infection among drug users-findings from a systematic review and meta-analysis.?Int J Environ Res Public Health, 2019,16:2345.
[4] Mehta R, Kabrawala M, Nandwani S,et al. Safety and efficacy of Sofosbuvir and daclatasvir for hepatitis c virus infection in patients with β-thalassemia major. J Clin Exp Hepatol, 2018, 8:3-6.
[5] Huang CF, Yeh ML, Huang CI, et al. Ribavirin facilitates early viral kinetics in chronic hepatitis c patients receiving daclatasvir/asunaprevir. Gastroenterol Hepatol,2020,35:151-156.
[6] 王艳斌, 谢雯. 《丙型肝炎防治指南(2015年更新版)》解读. 中华实验和临床感染病杂志(电子版), 2015, 009:1-4.
[7] Wasitthankasem R,Vongpunsawad S,Poovorawan Y. Influence of host and viral factors on patients with chronic hepatitis c virus genotype 6 treated with pegylated interferon and ribavirin: a systematic review and meta-analysis. Intervirology, 2015,58:373-381.
[8] Gordon SC, Lamerato LE, Rupp LB, et al. Prevalence of cirrhosis in hepatitis c patients in the chronic hepatitis cohort study (checs): a retrospective and prospective observational study.?Am J Gastroenterol, 2015,110:1169-1178.
[9] 饶慧瑛, 段钟平, 王贵强,等. 《丙型肝炎防治指南 (2019年版)》重要更新要点. 中华肝脏病杂志, 2020, 28:129-132.
[10] Sun D, Dai M, Shen S, et al. Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors, and NS5B polymerase inhibitors in patients with chronic hepatitis c. Gene Expr, 2018,18:63-69.
[11] Han B, Martin R, Xu S, et al. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na?ve subjects. Antiviral Res, 2019,170:104574.
[12] Huang W, Wang M, Gong Q, et al. Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in chinese patients with chronic hepatitis c virus infection. Microb Drug Resist, 2019,25:944-950. |
